Meridian Hedged Equity Fund highlighted Royalty Pharma in its first-quarter 2026 investor letter, noting the stock performed well following another earnings beat and expectations for continued strength from established franchises. Royalty Pharma is the industry's largest buyer of biopharmaceutical royalties, partnering with innovators to co-fund late-stage clinical trials and acquiring existing royalties on approved therapies. The fund maintained its position throughout the quarter. Royalty Pharma shares gained 56.06% over the past 52 weeks and closed at $56.23 on June 26, 2026, with a market capitalization of $32.38 billion.
Royalty Pharma Plcearnings beat and positive fund letter highlight
Cboe Global Markets Inc